Federal Register
Notice: FDA has determined the regulatory review period for Pfizer’s Relpax (eletriptan hydrobromide) is 2,829 days for extending a patent which claims the human drug product. Relpax is indicated for the acute treatment of migraine, with or without aura, in adults. To view this notice, click here.